

**Brandes Investment Partners**  
**Global Equity Strategy Notes**  
**First Quarter 2026 (January 1 – March 31, 2026)**

The Brandes Global Equity Strategy declined 1.60% net of fees and 1.51% gross of fees, outperforming its benchmark, the MSCI World Index, which fell 3.57% in the quarter, and underperforming the MSCI World Value Index, which rose 1.18%.

<b>Annualized total return as of March 31, 2026</b>	<b>1-year</b>	<b>5-year</b>	<b>10-year</b>
Brandes Global Equity Composite (net)	22.29%	13.19%	11.32%
Brandes Global Equity Composite (gross)	22.66%	13.67%	11.87%
MSCI World Index	18.90%	10.26%	11.79%

Past performance is not a guarantee of future results. One cannot invest directly in an index. Returns include reinvestment of all dividends and are reduced by any applicable foreign withholding taxes, without provisions for income taxes, if any.

**Positive Contributors**

The energy sector rose significantly amid the geopolitical conflict in the Middle East, and our slight overweight, along with our stock selection, aided relative returns. Apart from energy, notable contributors included holdings in emerging markets and pharmaceuticals, as well as businesses favorably tied to AI-related demand. Additionally, our underweight to information technology, particularly software, aided relative performance.

All three of our energy sector holdings rose substantially during the period on the back of rising oil and natural gas prices. France-based integrated energy company TotalEnergies was the largest contributor to returns, while U.S.- based oilfield services company Halliburton and U.K -based Shell also rose.

Emerging market technology holdings also contributed significantly, led by South Korea-based technology hardware and semiconductor company Samsung Electronics and Taiwan-based Taiwan Semiconductor Manufacturing Company. Both stocks rose as they continued to benefit from significant artificial intelligence (AI) demand-driven spending, including the increasing need for memory semiconductors as well as leading edge semiconductor chips.

The supply disruption of many materials and chemicals coming from the Middle East led to increases in the price of many chemicals and U.S.-based materials and housing products company Westlake was another top contributor.

Pharmaceuticals were the strongest contributing industry, led by GSK (based in the U.K.), Takeda (based in Japan) and U.S.-based pharmaceutical companies Merck and Pfizer.

**Performance Detractors**

The most significant detractors during the quarter came from select technology-related holdings, particularly software and IT services, where share prices pulled back sharply amid heightened concerns around AI-driven disruption and broader risk-off sentiment. While this weakness detracted at the individual holding level, the portfolio's underweight to the sector helped mitigate the overall impact.

Germany-based software company SAP declined, reflecting broader concerns around enterprise software vendors facing increased competition and questions around how quickly AI-driven innovation might translate into incremental revenue growth. Despite these concerns, SAP continued to benefit from a deeply embedded customer base and long-term secular demand for enterprise resource planning solutions. We used the share price decline as an opportunity to add to our position.

Several of our IT service holdings declined, led by France-based IT services company Capgemini, U.S.-based EPAM Systems, and Cognizant Technology Solutions. These declines were consistent with broad weakness across IT services as investors reassessed how generative AI might affect traditional consulting and application development models. All three companies have been investing in higher-value digital offerings and their services remain deeply embedded in the

operations of large enterprise clients, while market sentiment during the quarter reflected worries that AI-driven automation could compress pricing and dampen discretionary IT spending.

Taiwan-based server and datacenter hardware company Wiyynn detracted, as volatility in AI-related infrastructure spending expectations weighed on sentiment.

Ireland-based contract research organization ICON was another significant detractor. During the quarter, the company disclosed an internal investigation into accounting practices that could result in previously reported revenue being overstated by less than 2%. This increased investor uncertainty and led to pressure on the share price.

### **Select Activity in the Quarter**

During the quarter, we initiated a position in France-based Sodexo, a global leader in food services and facilities management. Sodexo provides outsourced services to corporate, education, health care, and government clients in more than 40 countries, with a business model anchored by long-term contracts and high renewal rates. The company generates the majority of its revenue from onsite services, including contract catering and facilities management, where scale advantages and operational complexity create meaningful barriers to entry.

Sodexo has fallen out of favor after several years of operational challenges, including labor cost inflation, inconsistent execution across regions, and investor skepticism following the spin-off of its employee benefits business. In North America, the company has underperformed peers, which further weighed on the shares.

In our view, this pessimism has created an opportunity to invest in what we consider a well-positioned, cash-generative business at a valuation that does not reflect its long-term earnings power. We believe the market is underestimating Sodexo's ability to pass through cost inflation over time, improve margins through operational initiatives, and benefit from secular outsourcing trends across corporate and institutional customers. In our view, the company's global scale, diversified end markets, and recurring revenue profile should provide resilience across economic cycles.

At current valuation levels, Sodexo trades at a meaningful discount to our estimate of intrinsic value. We see an attractive margin of safety, supported by strong returns on capital, a solid balance sheet, and the potential for earnings recovery as execution improves.

We exited our position in U.S.-based health care distributor Cardinal Health during the quarter after the share price rose to our estimate of intrinsic value following a strong period of performance.

We first invested in Cardinal Health more than eight years ago. Its industry at that point had consolidated significantly, leaving U.S. prescription drug distribution dominated by a small number of large players. At the time of our initial investment, we believed the market was underappreciating the durability of Cardinal Health's cashflow profile, its scale advantages, and the potential for improved profitability through better execution and portfolio focus, particularly within its higher margin medical products and services businesses.

Over our holding period, the investment case evolved as industry headwinds and idiosyncratic risks were repeatedly incorporated into the valuation. These issues included prolonged uncertainty around opioid litigation, which we monitored closely through various settlement scenarios, as well as competitive concerns related to Amazon's entry into the pharmacy business. While these risks were meaningful, we believed they were manageable and increasingly reflected in the share price over time.

In more recent years, Cardinal Health's fundamentals improved, and investor sentiment shifted. The company demonstrated strong cash generation, continued to return capital to shareholders, and pursued targeted acquisitions in specialty and at-home medical supply services. As execution improved and uncertainty diminished, the market re-rated the shares. With this strong performance, the stock price was approaching our estimate of intrinsic value, so we elected to divest the position and redeploy capital into opportunities where we see a more compelling margin of safety.

## Current Positioning

As of March 31, 2026, the portfolio remains meaningfully differentiated from the benchmark. Relative to the MSCI World Index, we maintained an overweight to consumer staples and health care and a substantial underweight to information technology, particularly software and semiconductors.

The quarter was marked by a sharp selloff across software and IT services as markets reassessed how artificial intelligence may disrupt traditional business models and industry economics. While we recognize that AI will be disruptive over time, we believe part of the recent selloff reflected broad risk reduction and valuation compression rather than uniform deterioration in near-term fundamentals. During the volatility, we added selectively to companies where we believe long-term competitive advantages remain intact.

Geographically, we hold overweight positions in the United Kingdom, France and emerging markets, while remaining underweight in the United States and Japan. We believe the differences between the strategy and the MSCI World Index make it an excellent complement and diversifier to passive and growth-oriented strategies.

Global value stocks continued to trade within the least expensive quartile relative to growth stocks (MSCI World Value vs. MSCI World Growth) since these style indices began. This is evident across various valuation measures, including price/earnings, price/cashflow and enterprise value/sales. Historically, such discount levels often signaled attractive subsequent relative returns for value stocks during subsequent periods. This is encouraging because our strategy, guided by our value philosophy and process, has had the tendency to do better than the value index when that index exceeded the broad benchmark.

Looking ahead, we are excited about the long-term prospects of companies held by the strategy, which in aggregate trade at more compelling valuation levels than the benchmark, in our opinion.

For term definitions: <https://www.brandes.com/termdefinitions>

For index definitions, please refer to <https://www.brandes.com/benchmark-definitions>.

The margin of safety for any security is the discount of market price to our estimate of intrinsic value.

MSCI has not approved, reviewed or produced this report, makes no express or implied warranties or representations and is not liable whatsoever for any data in the report. You may not redistribute the MSCI data or use it as a basis for other indices or investment products.

The foregoing Quarterly Commentary reflects the thoughts and opinions of Brandes Investment Partners® exclusively and is subject to change without notice. The information provided in the commentary should not be considered a recommendation to purchase or sell any particular security. It should not be assumed that any security transactions, holdings or sectors discussed were or will be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance discussed herein. International and emerging markets investing is subject to certain risks such as currency fluctuation and social and political changes; such risks may result in greater share price volatility. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that the securities sold have not been repurchased. The actual characteristics with respect to any particular account will vary based on a number of factors including but not limited to: (i) the size of the account; (ii) investment restrictions applicable to the account, if any; and (iii) market exigencies at the time of investment. Securities of small companies generally experience more volatility than mid and large sized companies. Although the statements of fact and data in this report have been obtained from, and are based upon, sources that are believed to be reliable, we cannot guarantee their accuracy, and any such information may be incomplete or condensed. Strategies discussed are subject to change at any time by the investment manager in its discretion due to market conditions or opportunities. The Brandes investment approach tends to result in portfolios that are materially different than their benchmarks with regard to characteristics such as risk, volatility, diversification, and concentration. Please note that all indices are unmanaged and are not available for direct investment. Past performance is not a guarantee of future results. No investment strategy can assure a profit or protect against loss. Market conditions may impact performance. The performance results presented were achieved in particular market conditions which may not be repeated. Moreover, the current market volatility and uncertain regulatory environment may have a negative impact on future performance. The margin of safety for any security is defined as the discount of its market price to what the firm believes is the intrinsic value of that security. The declaration and payment of shareholder dividends are solely at the discretion of the issuer and are subject to change at any time.

**United States:** Issued by Brandes Investment Partners, L.P., 4275 Executive Square, 5th Floor, La Jolla, CA 92037.

**Singapore/Asia:** FOR INSTITUTIONAL/ACCREDITED INVESTOR USE ONLY. Issued by Brandes Investment Partners (Asia) Pte Ltd., The Gateway West, 150 Beach Road, #35-51, Singapore 189720. Company Registration Number 201212812M. ARBN:164 952 710. This document is for "institutional investors" or "accredited investors" as defined under the Securities and Futures Act, Chapter 289 of Singapore and may not be distributed to any other person. This document is being provided for information purposes only. Incorporated in Singapore in 2012, Brandes Investment Partners (Asia) Pte Ltd (Brandes Asia) provides portfolio management services to clients in Asia (as permitted under local law). Brandes Investment Partners, L.P., a U.S. registered investment adviser and a sister entity to Brandes Asia, provides research, portfolio construction and other support to Brandes Asia.

**Canada:** FOR REGISTERED DEALERS AND THEIR REGISTERED SALESPERSONS' USE ONLY. NOT FOR DISTRIBUTION TO INVESTORS. Distributed by Brandes Investment Partners & Co., 6 Adelaide Street East, Suite 900, Toronto, ON, M5C 1H6. This communication is for information purposes only and should not be regarded as a sales communication or as advice regarding any financial product or services.